

SUMMARY**SOLID ORAL PHARMACEUTICAL FORMULATION OF MODIFIED RELEASE
THAT CONTAINS AN ACID LABILE BENZIMIDAZOLE COMPOUND**

- The pharmaceutical formulation consists of a number of pellets that comprise an inert nucleus, a layer with the active ingredient, one or more intermediate layers that comprise at least a system of modified release, and an external layer of enteric coating. These pellets can be obtained applying the different layers by means of fluid bed coating techniques using aqueous solutions or suspensions of the components of such layers. The pharmaceutical formulations can be hard gelatin capsules or tablets and are suitable for use in the prevention and treatment of disorders related to abnormal gastric acid secretion.
- 5 inert nucleus, a layer with the active ingredient, one or more intermediate layers that comprise at least a system of modified release, and an external layer of enteric coating. These pellets can be obtained applying the different layers by means of fluid bed coating techniques using aqueous solutions or suspensions of the components of such layers. The pharmaceutical formulations can be hard gelatin capsules or tablets and are suitable for use
- 10 in the prevention and treatment of disorders related to abnormal gastric acid secretion.

RECEIVED
U.S. POSTAL SERVICE
MAY 14 2002

EXPRESS MAIL LABEL
NO.: EL699731472US